Congestive Heart Failure Exacerbation Management

Initial Assessment and Monitoring

• The European Society of Cardiology recommends measuring plasma natriuretic peptide levels in all patients with acute dyspnea to differentiate acute heart failure from non-cardiac causes 1
• The European Society of Cardiology suggests performing ECG and echocardiography immediately, especially if cardiogenic shock is suspected 1
• Monitoring of symptoms, urine output, renal function, and electrolytes is recommended regularly during IV diuretic use by the American Heart Association 1, 3
• Assessment of vital signs, body weight, and clinical signs of systemic perfusion and congestion is advised by the American College of Cardiology 4
• Daily measurement of serum electrolytes, urea nitrogen, and creatinine is recommended during IV diuretic use or active titration of heart failure medications by the American Heart Association 3, 4

Diuretic Therapy

• The European Society of Cardiology recommends administering diuretics either as intermittent boluses or continuous infusion, adjusting dose and duration according to the patient's symptoms and clinical status 1, 2
• For patients with new-onset acute heart failure or decompensated chronic heart failure not on oral diuretics, the European Society of Cardiology suggests starting with 20-40 mg IV furosemide 1, 2
• The European Society of Cardiology advises that the initial IV dose for patients on chronic diuretic therapy should be at least equivalent to their oral dose 1

Management of Inadequate Diuretic Response

• Increasing the dose of loop diuretics is recommended by the American Heart Association for inadequate diuresis 2, 3
• Adding a second diuretic such as metolazone, spironolactone, or IV chlorothiazide is suggested by the American College of Cardiology for inadequate diuresis 3, 4
• Considering continuous infusion of a loop diuretic is advised by the American Heart Association for persistent fluid retention 3, 4

Continuation of Evidence-Based Therapies

• The European Society of Cardiology recommends attempting to continue evidence-based, disease-modifying therapies in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) 1, 3
• The American College of Cardiology suggests continuing ACE inhibitors/ARBs and beta-blockers during hospitalization unless the patient is hemodynamically unstable 3, 4
• Initiating these therapies before hospital discharge is recommended by the American Heart Association for patients not previously on them 3, 4

Special Considerations

• The European Society of Cardiology advises that inotropic agents should only be used if the patient is symptomatically hypotensive or hypoperfused due to safety concerns 1, 2
• Avoiding NSAIDs or COX-2 inhibitors is recommended by the European Society of Cardiology as they increase the risk of heart failure worsening and hospitalization 1
• The European Society of Cardiology suggests avoiding thiazolidinediones (glitazones) as they increase the risk of heart failure worsening 1

Transition to Discharge

• Transitioning from IV to oral diuretic therapy with careful attention to oral dosing and electrolyte monitoring is recommended by the American Heart Association 3, 4
• Providing comprehensive discharge instructions covering diet, medications, activity level, follow-up appointments, daily weight monitoring, and what to do if heart failure symptoms worsen is advised by the American College of Cardiology 3, 4
• Enrolling patients in a multidisciplinary care management program is recommended by the European Society of Cardiology to reduce the risk of heart failure hospitalization and mortality 1

Common Pitfalls to Avoid

• Underdosing diuretics in patients with chronic heart failure is a common pitfall, and ensuring the IV dose is at least equivalent to the oral dose is recommended by the European Society of Cardiology 1, 2
• Discontinuing evidence-based therapies unnecessarily during hospitalization is a pitfall, and the European Society of Cardiology advises against it 1, 3
• Failing to monitor electrolytes and renal function during aggressive diuresis is a common pitfall, and the European Society of Cardiology recommends regular monitoring 1, 3
• Not providing adequate discharge planning and follow-up instructions is a pitfall, and the American College of Cardiology suggests providing comprehensive instructions 3, 4